ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE

MLA

Stuart A. Grossman, et al. Actr-43. Genomic Analysis of Responders of Phase Ii Trial of Temozolomide and Trc-102 (Base Excision Repair Inhibitor) in Bevacizumab-Naïve Glioblastoma at First Recurrence. Nov. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....56ca7fae9a7c5c914f2fe1227a24defb&authtype=sso&custid=ns315887.

APA

Stuart A. Grossman, Glenn J. Lesser, Timothy F. Cloughesy, Jaleh Fallah, Manmeet S Ahluwalia, Tobias Walbert, Michael E. Berens, Harshil Dhruv, Lisa Rogers, Louis B. Nabors, Patrick Y. Wen, Xiaobu Ye, Matthias Holdhoff, David M. Peereboom, & Jan Drappatz. (2019). Actr-43. Genomic Analysis of Responders of Phase Ii Trial of Temozolomide and Trc-102 (Base Excision Repair Inhibitor) in Bevacizumab-Naïve Glioblastoma at First Recurrence.

Chicago

Stuart A. Grossman, Glenn J. Lesser, Timothy F. Cloughesy, Jaleh Fallah, Manmeet S Ahluwalia, Tobias Walbert, Michael E. Berens, et al. 2019. “Actr-43. Genomic Analysis of Responders of Phase Ii Trial of Temozolomide and Trc-102 (Base Excision Repair Inhibitor) in Bevacizumab-Naïve Glioblastoma at First Recurrence,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....56ca7fae9a7c5c914f2fe1227a24defb&authtype=sso&custid=ns315887.